{"name":"Kite Systems","slug":"kite-systems","ticker":"","exchange":"","domain":"","description":"Kite Systems is a specialized biotechnology company focused on developing innovative delivery systems for medical cannabis. The company's lead product, the cannaHALER, is in Phase 1 clinical trials and aims to provide a novel inhalation method for cannabis-based treatments.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9VVDBaQVBhMmNHelZFX0ZsVndZLTF4eUFKRWJVdjBBRWFaZ09VQnJvSHdEUFVYMXFzSjh6S0haYmNNZ1lobDM5cDN6SDc2SnlJSkE?oc=5","date":"2026-04-05","type":"regulatory","source":"Oncodaily","summary":"Oncology Biotech Updates This Week: $12B+ M&A Wave, Kite Pharma CAR-T Approval, and AI-Driven Deals Reshape the Sector - Oncodaily","headline":"Oncology Biotech Updates This Week: $12B+ M&A Wave, Kite Pharma CAR-T Approval, and AI-Driven Deals Reshape the Sector","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYkR5THpjMy1xV05wVFpRblFjeDZkSURvYUhKc0VoR1F1UEFMeVp4aUpfa0ltSjNoZ0tQbkRRVnFtT1BNZGlVcGN5UHpWbzI0Y3R0VTFqOXBwcGdaSkdWSTdPS29QNlFKRVRyTVJDT0s5SVVyN0FWN1ZhaFo3bkhzaEVZM1gyRUxlMWczSkI2RVRXQ3lZUzFlZl80UmU5c3VIbnpERHFDYVdTQQ?oc=5","date":"2025-09-05","type":"trial","source":"Ship Technology","summary":"K LINE completes phase one development of Seawing automated kite system - Ship Technology","headline":"K LINE completes phase one development of Seawing automated kite system","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQbld2T1REUGFQeUdJVWJDWmw4MmhpLXpUTTJHNDg4RDJIYjFySS1ERXF4UkgzY25sQjN0Y2o0Ni1JaENRbFJRNXFkZkl3RTNZY0pwLThHR005dDdtUVdENWdvTF9sUVJlZnMzVkVqaWJUQUJvRkYzOWFzWUswTzdYRE1IcEpGbEh5bXZFWkk2VjhUd2s?oc=5","date":"2025-08-21","type":"deal","source":"statnews.com","summary":"Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million - statnews.com","headline":"Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNeWZlLUZIX0sxN29vXy02OVBJeXU2bXlGeUlXSVV2RnV2VEFaX3FvTGt2RjFrSFdTd29PS2x3YUdEallkc2hlRnFLSUc3bFIxX0dZLWRBVEVZaXNkWThkZlZnbzdyWUZpTTJzU3ZXeXIyVTRXWVBFTWpuVllaV0s4MnVMaDBNZnRfUkQ2bDJfR2RPbThCTjNhSko5Ujd4R3dVSTN3NzgxeGd0bm1obkpGck1HMA?oc=5","date":"2025-07-01","type":"trial","source":"Contract Pharma","summary":"AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies - Contract Pharma","headline":"AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxONUZueFlyanJJdkhaNXJ2aUp0WlVIZS1sUGtjODdjMURXZVFLS2RUTTQzOXBnQldQNklYVVFfV3R1MVVEamF3UV9ONnBmeXlkem5TaVNFUVM2M3prcDdZd29Yb2ZwWHBtSXdfVEZYdkg3UlpqZElNdlpBNjN6TlFHcVU0V2lQMl9NeFNGdmY4aVktWFRPTW9ISmZFY0FKa3dDWm13LU13?oc=5","date":"2020-04-20","type":"deal","source":"Targeted Oncology","summary":"Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration - Targeted Oncology","headline":"Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNV1NocDJkRng5SnlKZ01tYzNjR1J4N3JWR2RyVjBfVkNfOFFFTzVBek9taVJyY2NNcTE0X2JBV29TbklPWF81ZWViaVZrbm44VjJhZkVMdjhRU0RFeXNDNTlpY183Z3RnVVlCUFlnWWdZZ3JXdGt5SmJqX05pQ0M2bVFZWE5VbEw4d2pRejJYVDVaazgzYWt5blhCVG9uSGg0MlN1Q1hORHN6a18zTnhz?oc=5","date":"2019-10-17","type":"pipeline","source":"Pharmaceutical Technology","summary":"Kite Pharma’s Biopharmaceutical Manufacturing Facility, Netherlands - Pharmaceutical Technology","headline":"Kite Pharma’s Biopharmaceutical Manufacturing Facility, Netherlands","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaXBNRVh6SWF3ZkRnNm9aaEFHanNCaUhpYllrR25hMjUtNnNuTGxSbkNyRnBjeHl5cmlEeUt6ZTkyMEtvOUtkX2Mya3Zyc1hWenlOYTJXMnBraFJJSmJlcFJlVTQtSnZra0xHMlNGWUJOOVZndVJrcFFXdHhyQnl1QkM3a2NFaFNSMjUtV2ZkdENHcXRYTXE3ZWhnbW5fc2lpVDNBdlVBTlo?oc=5","date":"2019-09-30","type":"pipeline","source":"BioProcess International","summary":"Yescarta 2.0? How Kite plans to scale out CAR-T therapies - BioProcess International","headline":"Yescarta 2.0? How Kite plans to scale out CAR-T therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTGlacjJwaGVvSjhaNFAwY0tPSmREaUQ3bHQ0T0xZNHFjVm53YWV4dDBkNnk2OU9kMWY0Zml6VkhuZFh1RHlEV1UyYmdkNlNSUzRNUDRCc1ppSGJEaFFobDdvV3VmckFNQ1ZzblhUcVktVXktREJYY3R5dTFraXlEelFsaUxNeXh0d1gtMlNSMlBuaWdhTGNtVU91ZDRPSXBFTWNCeVhYT0RnZTVrNklnNUlHLVhGcXBvOFVRZDduM2E?oc=5","date":"2017-09-01","type":"pipeline","source":"Fierce Pharma","summary":"Gilead finds CAR-T manufacturing costly but says Kite's is 'superb' and cost-efficient - Fierce Pharma","headline":"Gilead finds CAR-T manufacturing costly but says Kite's is 'superb' and cost-efficient","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPQU1XMjRzdzBRQkpWZGFfM1JKZUhRcmZlemtnN3BkLTlCaDFzSnVYU0FSV29fZEpkdW0wS0lRUDJQaGlJLTFjUkNYaVFfQ0pnY3FBdUFsS2dxbVdqTG1FQzZMNlJUWHlEZnR6Wi1TVEZwZWtNcFdDSjFpcEhNZ3BaRWpvNnV2Zw?oc=5","date":"2017-08-28","type":"deal","source":"C&EN","summary":"Gilead to acquire Kite Pharma for $11.9 billion - C&EN","headline":"Gilead to acquire Kite Pharma for $11.9 billion - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNOFp5eGZReHJmMm9CU2NYSHZlT0M3dWZwV2ZUTS1JOWEzOTVIS28tUU04a3FDYXhVZmNPa3h1MDZkRDBMcXJCa0o3UkJaVHJ3Y0U2WHlobnVDTjlPbllxeU5iMTFIOVl3OEhZRTV1ZGRtdnd2RmZXWjJONGl1Nk4tbWFOOHJfSm1RNFE?oc=5","date":"2017-08-28","type":"deal","source":"The New York Times","summary":"Gilead to Buy Kite, Maker of Cancer Treatments, for $11.9 Billion (Published 2017) - The New York Times","headline":"Gilead to Buy Kite, Maker of Cancer Treatments, for $11.9 Billion (Published 2017)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZ29pWkhTMjhlZWs1bTA4N2J2UVdjN1dobnp6ZkRuUVg2SktoNzVDcXpOX2tRcnhlZ2hHOUkweTdHcjdEbExRdjBUQUs2YUhidWdCamw4eTZmTzF2cjFYbUlBQ0s1OGxJbmlYbVlZRFBEODB6eXY5Zy1weVVOcG4zeGEzM1paV01nSWpELTVuak1XTEVoMXNKc3pwOHFJN1h3MzVLMk01R0o?oc=5","date":"2017-05-08","type":"regulatory","source":"Fierce Biotech","summary":"Investors spooked by Kite CAR-T death, but biotech remains confident - Fierce Biotech","headline":"Investors spooked by Kite CAR-T death, but biotech remains confident","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOcW1CYmZoWTlvTWt5U1Y4TDg4RXplRURwWElrMWJlZGNKT01EY2VaUmZzSWRiT1ZKVk1fcmNRZmctRllDMTZTaGh5VUlMSHhxMHNIeVVLS1ZESkx0bE5jY1FrRWFodjhwcVA1bnhCTy1wU3pSNVVWSERsNE42REJubndB?oc=5","date":"2016-07-26","type":"deal","source":"BioPharma Dive","summary":"Kite eyes off-the-shelf T-cell therapies with UCLA research deal - BioPharma Dive","headline":"Kite eyes off-the-shelf T-cell therapies with UCLA research deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}